FDA Review Of Merck’s Novel HIV Drug Isentress Shows No Clear Efficacy Or Safety Concerns

FDA is asking its Antiviral Drugs Advisory Committee at the Sept. 5 meeting to consider HIV general treatment issues and postmarketing strategies for Merck’s integrase inhibitor, Isentress (raltegravir), which is up for accelerated approval.